DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
it’s - 1 — it’s - 1 ” - 1 Ahmad Jayedi - 1 haven’t - 1 Robert Gabbay - 1 Gabbay wasn’t - 1 Carmen Cuthbertson - 1
Top related locs:
Iran United States United Kingdom Japan Spain
Top related orgs:
CNN’s - 1 CNN - 1 British - 1 of Sports Medicine - 1 Health Research Center - 1 Semnan University of Medical Sciences - 1 American Diabetes Association - 1 East Carolina University - 1

Search resuls for: "” Gabbay"


2 mentions found


☆ Walking pace could impact diabetes risk, study finds
  + stars: | 2023-11-28 | by ( Kristen Rogers | ) edition.cnn.com   time to read: +5 min
Brisk walking is associated with a nearly 40% lower risk of developing type 2 diabetes later in life, according to the study published Tuesday in the British Journal of Sports Medicine. But prior findings haven’t offered much guidance on the optimal habitual walking speed needed to lower diabetes risk, and comprehensive reviews of the evidence are lacking, the authors said. Going a certain pace during your walk may help lower your type 2 diabetes risk, according to a new study. Walking at a “fairly brisk” pace meant a 24% lower risk than those who easily or casually walked. Each kilometer increase in walking speed above brisk was associated with a 9% lower risk of developing the disease.
Persons: it’s, — it’s, ”, Ahmad Jayedi, haven’t, Robert Gabbay, Gabbay wasn’t, Carmen Cuthbertson, wasn’t, Gabbay, Dr, Michio Shimabukuro, Shimabukuro wasn’t, Borja del Pozo Cruz, ” del Pozo Cruz, ” Gabbay Organizations: CNN’s, CNN, British, of Sports Medicine, Health Research Center, Semnan University of Medical Sciences, American Diabetes Association, East Carolina University, Fukushima Medical University School of Medicine, University of Cadiz, US Centers for Disease Control Locations: Iran, United States, United Kingdom, Japan, Spain
☆ FDA approves first treatment to delay onset of type 1 diabetes
  + stars: | 2022-11-17 | by ( Jen Christensen Brenda Goodman Cnn | Jen Christensen | Brenda Goodman Cnn | ) edition.cnn.com   time to read: +8 min
CNN —A biologic therapy that delays the onset of type 1 diabetes received approval from the US Food and Drug Administration on Thursday. The most common side effects reported in the trial participants were low white blood cells and lymph cells, rash and headache. Without insulin, blood sugar can build up in the bloodstream and break down the body’s own fat and muscle. With Tzield, doctors would screen individual family members of people with type 1 diabetes to see whether they have those specific antibodies. As of 2019, about 1.9 million people have type 1 diabetes in the United States, according to the American Diabetes Association, including 244,000 children and adolescents.
0 next >>
Total: 2